T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Daniela Schmid(Roche (Switzerland)), Darrell J. Irvine(Howard Hughes Medical Institute), Regina Bou-Puerto(Memorial Sloan Kettering Cancer Center), Nikita Subedi(Dana-Farber Cancer Institute), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Christina Hartl(Io Therapeutics (United States)), James Maiarana(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Michael S. Goldberg(Jefferson Einstein Philadelphia Hospital), Yiran Zheng(Institute of Bioengineering and Nanotechnology), Adam N.R. Cartwright(Harvard University), Chun Gwon Park(Sungkyunkwan University)
RePEc: Research Papers in Economics
November 1, 2017
Cited by 0

Related Papers

An immunogenic personal neoantigen vaccine for patients with melanoma
|Nature|2017|3k
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
|Science|2018|1.5k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k